



November 23, 2020

RE: Suboxone® Film Coverage, Tirosint® Capsule Coverage

Dear SoonerCare Provider,

Suboxone® Film Coverage

Effective January 1, 2021, Suboxone® films, brand and generic, will be non-preferred. Only generic buprenorphine/naloxone sublingual tablets will be preferred. Authorization of buprenorphine/naloxone films will require a patient-specific, clinically significant reason why generic buprenorphine/naloxone sublingual tablets are not appropriate. Members currently utilizing Suboxone® films will not be grandfathered.

Tirosint® Capsule Coverage

Effective December 7, 2020, Tirosint® capsules will require prior authorization. Members currently using Tirosint® capsules will be grandfathered. The prior authorization criteria for reimbursement is as follows:

Tirosint® (levothyroxine capsule) and Tirosint®-SOL (levothyroxine oral solution) Approval Criteria:

1. An FDA approved diagnosis of one of the following:
 - a. Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism; or
 - b. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer; and
2. A patient-specific, clinically significant reason why the member cannot use all other formulations of levothyroxine must be provided. For the oral solution, a reason why the member cannot use the levothyroxine tablet, even when the tablets are crushed, must be provided; and
3. Prescriber must verify member has been compliant with levothyroxine tablets at a maximum dose for at least 8 weeks; and
4. Prescriber must verify that member has not been able to achieve normal thyroid lab levels despite maximum dosing and compliance with levothyroxine tablets.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS



ADDRESS

P.O. Box 26901; ORI W-4403
Oklahoma City, OK 73126



WEBSITES

okhca.org
mysoonerca.org



PHONE

(800) 522-0114, option 4
Fax: (800) 224-4014